ClinicalTrials.gg
RecruitingNCT07937462Updated Nov 16, 2026

The Efficacy and Safety of DLBS1442 in Patients With Primary Dysmenorrhea

A Phase 2/3 interventional study of DLBS1442 and Placebo in Primary Dysmenorrhea, sponsored by Dexa Medica Group. Recruiting at 1 site in Indonesia. Open to female participants aged 18 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Dexa Medica Group · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2026, registered Nov 2026).
  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 21 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to evaluate whether DLBS1442 can alleviate primary dysmenorrhea in young adults aged 18 to 21 years. The main question it aims to answer is:

1. Does DLBS1442, at doses of 100 mg and 200 mg, reduce dysmenorrhea pain compared with placebo, as measured by the change from baseline in Visual Analogue Scale (VAS) pain score at predefined time points after the first dose?

Researchers will compare DLBS1442 100 mg, DLBS1442 200 mg, with placebo to determine whether DLBS1442 is more effective in reducing dysmenorrhea pain.

Participants will:

  1. Take DLBS1442 or placebo three times daily for up to 5 consecutive days during one menstrual cycle. Treatment may be discontinued earlier if pain completely resolves (VAS = 0).
  2. Return to the study site on Day 6 after Visit 1 for assessment of study drug compliance, diary review, return of unused study medication and packaging, and study-related evaluations.
  3. Record the Visual Analogue Scale (VAS) pain score before each study drug administration.
  4. Complete the quality-of-life questionnaire on Days 1, 2, 3, and 6.
  5. Record any adverse events and concomitant medications used throughout the study.
  6. Record the use of rescue medication (paracetamol), including the VAS pain score immediately before each rescue medication dose.
Read the detailed description

Primary dysmenorrhea is a prevalent gynecological condition affecting adolescents and young women and is characterized by recurrent menstrual pain in the absence of identifiable pelvic pathology. Although nonsteroidal anti-inflammatory drugs are considered the standard treatment, some patients experience inadequate pain relief or are unable to tolerate these medications. Therefore, the development of alternative therapeutic options with favorable efficacy and safety profiles remains clinically important.

DLBS1442 is a standardized bioactive fraction derived from Phaleria macrocarpa (Mahkota Dewa), an Indonesian medicinal plant. Pharmacological studies have demonstrated anti-inflammatory and immunomodulatory properties of DLBS1442, suggesting its potential to reduce menstrual pain associated with inflammatory pathways in primary dysmenorrhea.

This is a Phase II/III, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging clinical trial designed to evaluate the efficacy and safety of DLBS1442 in female participants aged 18 to 21 years with primary dysmenorrhea. Eligible participants will be randomized in a 1:1:1 ratio to receive DLBS1442 100 mg, DLBS1442 200 mg, or matching placebo for up to 5 consecutive days during one menstrual cycle. Study treatment may be discontinued before Day 5 if complete pain relief (VAS = 0) is achieved, while study assessments will continue according to the protocol.

Efficacy will be evaluated using serial assessments of menstrual pain intensity with the Visual Analogue Scale (VAS) following the first dose and throughout the treatment period. Health-related quality of life will be evaluated using the EQ-5D-5L questionnaire. Rescue medication (paracetamol) will be permitted according to predefined protocol criteria and documented throughout the study. Safety evaluations will include monitoring of adverse events, concomitant medication use, physical examinations, and laboratory assessments in participants with a history of hepatic or renal impairment.

This study is designed to characterize the dose-response relationship of DLBS1442 and to provide evidence regarding its efficacy and safety as a potential treatment for primary dysmenorrhea.

02

Conditions studied

  • Primary Dysmenorrhea

Browse trials for

Keywords

  • primary dysmenorrhea
  • dysmenorrhea
  • DLBS1442
  • Phaleria macrocarpa
03

In context

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

This study's planned enrollment of 210 is above the median of 62 across 363 interventional studies indexed under Dysmenorrhea.

Browse Dysmenorrhea studies →

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 21 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged 18 to 21 years with primary dysmenorrhea.
  • Moderate to severe menstrual pain at enrollment.
  • Able and willing to provide written and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Known to the product or its components.
  • Secondary dysmenorrhea or other significant gynecological conditions.
  • Pregnancy, breastfeeding, or hormonal use.
  • Significant medical conditions or acute illness that may interfere with study participation or safety.
  • Recent use of analgesic, anti-inflammatory, herbal, or other dysmenorrhea-related treatments.
  • Any condition that, in the investigator's opinion, would make the participant unsuitable for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    DLBS1442 100 mg

    Participants randomized to this arm will receive one DLBS1442 100 mg capsule and one matching placebo capsule three times daily for up to 5 consecutive days during one menstrual cycle. Treatment may be discontinued if complete pain relief (Visual Analogue Scale \[VAS\] = 0) is achieved.

    Drug: DLBS1442 · Drug: Placebo

  • Experimental
    DLBS1442 200 mg

    Participants randomized to this arm will receive two DLBS1442 100 mg capsules three times daily for up to 5 consecutive days during one menstrual cycle. Treatment may be discontinued if complete pain relief (Visual Analogue Scale \[VAS\] = 0) is achieved.

    Drug: DLBS1442

  • Placebo comparator
    Placebo of DLBS1442

    Participants randomized to this arm will receive two matching placebo capsules three times daily for up to 5 consecutive days during one menstrual cycle. Treatment may be discontinued if complete pain relief (Visual Analogue Scale \[VAS\] = 0) is achieved.

    Drug: Placebo

Interventions

  • DrugDLBS1442

    DLBS1442 is supplied as 100 mg oral capsules. Participants will receive either : 1. DLBS1442 100 mg + Placebo; or 2. DLBS1442 100 mg + DLBS1442 100 mg three times daily for up to 5 consecutive days during one menstrual cycle, according to the randomized treatment assignment. Treatment may be discontinued once complete pain relief is achieved (Visual Analogue Scale \[VAS\] = 0).

    Also known as: Dismeno

  • DrugPlacebo

    Matching placebo capsules identical in appearance to DLBS1442 capsules. Participants will receive either one placebo capsule together with one DLBS1442 100 mg capsule or two placebo capsules three times daily for up to 5 consecutive days during one menstrual cycle, according to the randomized treatment assignment. Treatment may be discontinued once complete pain relief is achieved (Visual Analogue Scale \[VAS\] = 0).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Visual Analogue Scale (VAS) Pain Score Within 6 Hours After the First Dose

    Change from baseline in menstrual pain intensity measured using the Visual Analogue Scale (VAS). The VAS ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain assessments will be performed at baseline and at 30 minutes, 1 hour, 2 hours, 4 hours, and 6 hours after the first dose.

    Time frame: Baseline to 6 hours after the first dose.

Secondary outcomes

  1. Change From Baseline in Visual Analogue Scale (VAS) Pain Score During the 5-Day Treatment Period

    Change from baseline in menstrual pain intensity measured using the Visual Analogue Scale (VAS). The VAS ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain assessments will be performed before each scheduled study drug administration during the treatment period.

    Time frame: Baseline through Day 5

  2. Proportion of Participants Achieving Pain-Free Status

    Percentage of participants achieving a pain-free state, defined as two consecutive VAS assessments with a score of 0.

    Time frame: Baseline through Day 5

  3. Number of Study Drug Doses Administered Until Complete Pain Relief

    Number of doses of the assigned study treatment (DLBS1442 100 mg, DLBS1442 200 mg, or placebo) administered until complete pain relief, defined as a Visual Analogue Scale (VAS) score of 0, or until the end of the treatment period, whichever occurs first.

    Time frame: First dose through Day 5

  4. Use of Rescue Medication (Paracetamol)

    Number of participants requiring rescue medication and the amount of rescue medication used during the study period.

    Time frame: Baseline through Day 5

  5. Time From First Dose of Study Drug to First Use of Rescue Medication

    Time elapsed from the first administration of the assigned study treatment (DLBS1442 100 mg, DLBS1442 200 mg, or placebo) to the first administration of rescue medication (paracetamol).

    Time frame: First dose through Day 5

Other outcomes

  1. Change From Baseline in EQ-5D-5L Health-Related Quality of Life Score

    Change from baseline in health-related quality of life assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The EQ-5D-5L descriptive system consists of five dimensions with five response levels. Responses are converted to a utility index using the Indonesian EQ-5D-5L value set, with higher utility index values indicating better health status. Assessments will be performed on Days 2, 3, and 6.

    Time frame: Baseline through Day 6 (assessed on Days 2, 3, and 6)

  2. Incidence and Characteristics of Adverse Events

    All adverse events (AEs) occurring during the study will be recorded and summarized by event type, severity, and investigator-assessed relationship to the study treatment.

    Time frame: Baseline through Day 6.

07

Study locations

1 of 1 sites recruiting
  • Klinik Pratama Equilab International
    Jakarta, Jakarta Special Capital Region 12430, Indonesia
    Recruiting
    • Danang A Yunaidi, MD · Contactdanang@equilab-int.com · +628561228485
    • Danang A Yunaidi, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07937462
Lead sponsor
Dexa Medica Group
Collaborators
PT Equilab International
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Aug 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Danang A Yunaidi, MD
Contact
danang@equilab-int.com
+628561228485
Liana W Susanto, MBiomed
Contact
liana.wijaya@dexa-medica.com
+628129507176
Danang A Yunaidi, MD
principal investigator · Klinik Pratama Equilab International

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion